Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

2 Customer Reviews

  • (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.

    Leukemia, 2018, 32(1):139-148. Midostaurin (PKC412) purchased from Selleck.

    PKC412 is cytotoxic to human HNSCC cells. The established HNSCC cells (SQ20B and SCC‐9 cell lines), primary human oral carcinoma cells (“Primary1/2”) and primary oral epithelial cells (“Epithelial”), were treated with indicated concentrations of PKC412. Cells were then cultured in complete medium for the applied time, and cell survival was tested by the MTT assay (a, d) and colony formation assay (c). Cell death was tested by the trypan blue staining assay (b). “CTR” indicates medium‐treated control group (for all figures). All the experiments were repeated five times, and similar results were obtained. n = 5 for each assay. Error bars indicate mean ± SD (for all figures). *p < 0.05 versus group “CTR.” HNSCC, head and neck squamous cell carcinoma; MTT, 3‐(4,5‐dimethyl‐thiazol-2-yl)2,5-diphenyl tetrazolium bromide; OD, optical density; PKC, protein kinase C

    J Cell Physiol, 2018, 233(12):9437-9446. Midostaurin (PKC412) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells M2PPSWN6fG:2b4jpZ4l1gSCjc4PhfS=> MmTsO|IhcA>? MnvZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVA:OTJibl2= NYewfnNYOTl4NUS0NFg>
RS4-11 cells NXr3SZIyTnWwY4Tpc44h[XO|YYm= NIXuSYMzKGh? NXq3WlZ6UW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDSV|QuOTFiY3XscJMh[W[2ZYKgNkBpenNiYomg[Yxm[3S{b3Po[Y1qdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwQVE{KG6P NYjTeGNKOTl4NUS0NFg>
CGTH-W-1 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUfNOFJGUW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR{Lk[1JO69VQ>? NFnMZ3VUSU6JRWK=
SW982 cell MnLqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkL0TY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1MlU5KM7:TR?= MX3TRW5ITVJ?
human EoL-1-cell cell NFTsOHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mor4TY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTJwMEigcm0> NXztcI0xW0GQR1XS
MOLM-13 cells MnryS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml3jO|IhcA>? MoHhTY5pcWKrdHnvckBw\iCITGSzJGlVTCCqZYTldo97gWexdYOgcZV1[W62IHnuJIh2dWGwIF3PUG0uOTNiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBIUTVyPUCuNFU2KM7:TR?= M3vyWVI3ODhzMEKz
KASUMI-1 cell MlL3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3PHbWlvcGmkaYTpc44hd2ZiaIXtZY4hU0GVVV3JMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MEG2JO69VQ>? NGLLRodUSU6JRWK=
NCI-H1755 cell NHTLV3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\sNZhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[yO|Mh|ryP M1H1fnNCVkeHUh?=
human MES-SA cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmLZTY5pcWKrdHnvckBw\iCqdX3hckBOTVNvU1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA4PTR2IN88US=> MV;TRW5ITVJ?
human HCC1395 cell MnfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PDJ6IN88US=> NXLlTot2W0GQR1XS
human D-336MG cell M3PKRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=> MmC2V2FPT0WU
CHP-212 cell M2D4V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXQZXlKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6N{ezJO69VQ>? Mnz6V2FPT0WU
human KM12 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{Lw[2lvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFkzPzVizszN MnLIV2FPT0WU
A204 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYq0ZZp1UW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODB3MjFOwG0> NGjGfWpUSU6JRWK=
CAL-51 cell MkW3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4TUcmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODdyOTFOwG0> MXjTRW5ITVJ?
human A431 cell M4nqeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxNlE3KM7:TR?= NXn6PVl7W0GQR1XS
NCI-H650 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXSWndKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMUewPEDPxE1? NGHtdJlUSU6JRWK=
A427 cell NHHZXWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUWyc|FYUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTlzODFOwG0> MUHTRW5ITVJ?
human 769-P cell NY\1T25mT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNlA5OiEQvF2= M2[wdnNCVkeHUh?=
SW1710 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojDTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{OzF4IN88US=> NIfvTWxUSU6JRWK=
human H4 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4X2NmlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGzPVY{KM7:TR?= NXHpeVhVW0GQR1XS
HT-1080 cell NWPqTJc3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWDBfmZxUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NkDPxE1? MnvuV2FPT0WU
human PANC-03-27 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXr1fnhUUW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlAzKM7:TR?= NVHTeotMW0GQR1XS
A375 cells M2HLRWN6fG:2b4jpZ4l1gSCjc4PhfS=> MUW3NkBp MUnUc5hq[2m2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1yLkG4JO69VQ>? MVixPVY2PDRyOB?=
human HOP-62 cell M{LGZWZ2dmO2aX;uJIF{e2G7 M2fhemlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDB5MzFOwG0> M3rmXHNCVkeHUh?=
human U031 cell NXTWfol1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF;Bc4VKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6Pjl6IN88US=> Mnr3V2FPT0WU
mouse BAF3 cells NY\rbZA1WHKxbHnm[ZJifGmxbjDhd5NigQ>? M3\ubGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczD0doFve2[xcn3l[EB4cXSqIGrOSlE6QC2IR1\SNUBkd26|dIL1Z5QtKEmFNUC9NE4zKM7:TR?= M4nBcFIyQTN4NUSy
human G-402 cell NFGzZmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPscWtKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zODJ3MzFOwG0> NH[xXGtUSU6JRWK=
human G-361 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4H1[WlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxQDV|IN88US=> MlO5V2FPT0WU
NCI-H810 cell M3PJSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmXRTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO NITKbIFUSU6JRWK=
NCI-H2030 cell Mn3zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MojkTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|MEC2JO69VQ>? MX3TRW5ITVJ?
human HCT-116 cell NIDmXHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHkeos4UW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{W2PEDPxE1? NUXod5Y3W0GQR1XS
human SNU-423 cell NEXsS|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNPXS12MkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PjV5IN88US=> MXzTRW5ITVJ?
human SCC-4 cell MkP1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2qxcmlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QTZ5IN88US=> MnrKV2FPT0WU
human SW48 cell MkjXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK2Olgh|ryP Mm\TV2FPT0WU
human SF295 cell MlmwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF7RS2VKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzJ3NzFOwG0> NH;4R4hUSU6JRWK=
MDA-MB-231 cell NYntOXdJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>? MoW4V2FPT0WU
A172 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK5NVUh|ryP NIXkRlJUSU6JRWK=
human BCPAP cell M{HQbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIPtSIZKdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTh5OTFOwG0> MX\TRW5ITVJ?
human COLO-792 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnDUWlKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{OUm3NkDPxE1? MWHTRW5ITVJ?
human DU-145 cell MlXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfYTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMyQDh7IN88US=> NHXyNZRUSU6JRWK=
NCI-H2122 cell NXzTNodsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M36zb2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkK4OUDPxE1? M3i2S3NCVkeHUh?=
human SK-UT-1 cell NHHjeZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> M{LZNXNCVkeHUh?=
LXF-289 cell NUS3[3dHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjvZ3ZKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OU[1JO69VQ>? M1fnfXNCVkeHUh?=
human NCI-H1792 cell M3PmXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzNyOU[g{txO NIPFXIJUSU6JRWK=
MCF7 cell NH7qW4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPt[ndpUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzJ5NDFOwG0> MVjTRW5ITVJ?
HCT-15 cell NVvOd|k2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M1OzJizszN NFfHeXRUSU6JRWK=
human NCI-H358 cell NF3ybmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnnkTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEO1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN3NUGg{txO M3fs[XNCVkeHUh?=
human HLE cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{O3OVIh|ryP NY[0WJhHW0GQR1XS
human SW1088 cell NYTmfm57T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV7TUYFCUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|N{m3JO69VQ>? NWfHN4FNW0GQR1XS
human K5 cell NELQZ4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXwTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP M3;3PXNCVkeHUh?=
human SR cell NGKyeWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJHNTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NkW3NUDPxE1? NHyxcmhUSU6JRWK=
human Calu-3 cell NWPGbnN4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjzboF[UW6qaXLpeIlwdiCxZjDoeY1idiCFYXz1MVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN4OEK1JO69VQ>? M{HiVXNCVkeHUh?=
human SK-MEL-30 cell M3KycGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzyXFdKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{m5NVMh|ryP NIjheXVUSU6JRWK=
human SW780 cell MljSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF;TWVVKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0> Ml;FV2FPT0WU
NCI-H1563 cell NUHvbpFzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1XhO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MUS4OEDPxE1? MX\TRW5ITVJ?
human MKN45 cell MnzZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLETY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFE6OzFizszN M1W2WHNCVkeHUh?=
MDA-MB-157 cell NIjofVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3fUfGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKwNVUh|ryP NV3Fc5l3W0GQR1XS
human NCI-H522 cell MnPvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fFbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR{MzFOwG0> MnvhV2FPT0WU
human A2780 cell NFHLbHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|UxOyEQvF2= MX\TRW5ITVJ?
human A498 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4D2N2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc3QTNizszN MnvQV2FPT0WU
human BxPC-3 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXX5cYgzUW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7M{[2JO69VQ>? M2rVUXNCVkeHUh?=
human A2058 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlXJTY5pcWKrdHnvckBw\iCqdX3hckBCOjB3ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVI5PDRizszN MkPaV2FPT0WU
human PC-14 cell NFqx[oVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzOcnlUUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO NIfpTlVUSU6JRWK=
human KG-1 cell Mmq5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIPibYFKdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU2PDF7IN88US=> MkXhV2FPT0WU
human A375 cell MnXsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUj1[npSUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PjFyMzFOwG0> M3XwdXNCVkeHUh?=
human SW1783 cell NWLQcVJjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmrqTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5OEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{OzdizszN NY\0cJQ2W0GQR1XS
human MKN1 cell M1v3RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHy0OoJKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> M{HzdXNCVkeHUh?=
NCI-H1650 cell M3PyVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh7MUdjhKDPxE1? M{jVTHNCVkeHUh?=
human HT-1376 cell M3TJTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFvEbGZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGzO|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl{OUG4JO69VQ>? NXTo[WliW0GQR1XS
SW872 cell NXjiRmlST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYPiVYpSUW6qaXLpeIlwdiCxZjDoeY1idiCVV{i3NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTR2NUmg{txO NIPEfnhUSU6JRWK=
human RT-112 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc1QDNizszN NX7Q[5RkW0GQR1XS
human HT-29 cell M13LSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1Kw[WlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4QTl4IN88US=> MkH6V2FPT0WU
human U-266 cell NUjqPY5FT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXzJcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFMxOiEQvF2= M13TNXNCVkeHUh?=
human HEL cell NWXTcXdST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1vvOmlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFUyPyEQvF2= Mom5V2FPT0WU
human KU812 cell NIrub2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xNVE3PCEQvF2= M{DKeHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID